The Committee discusses and makes recommendations on the safety and effectiveness of Pfizer’s Biologics License Application (BLA) 125769 (STN 125769/0), ABRYSVO for active immunization for the prevention of acute respiratory disease and lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older in a virtual meeting to be held on February 28 at 8:30 am. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Moderna, Pfizer: Top mRNA Innovator Stocks are Oversold
- Pfizer acquisition of Seagen could add $7B in sales, says JPMorgan
- Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says
- Pfizer (NYSE:PFE) Could Buy Seagen to Bolster Oncology Portfolio
- FDA Virtual Vaccines & Related Biological Products Advisory Committee Meeting